Clinical Trials

  • Principal Investigator:

    Philip L. De Jager, MD, PHD
    The Snapshot study aims to understand brain and spinal cord aging in healthy individuals and individuals with multiple sclerosis (MS). We aim to identify new tools that will help us to achieve successful brain aging in the general population and in people with an underlying autoimmune disease. A critical aspect of this study is that we are looking for individuals who are willing to donate their brain and spinal cord when they pass away; this will enable the investigators to understand which molecules in the brain made someone more or less likely to age successfully. The brains will be housed...
  • Principal Investigator:

    Sheng-Han Kuo, MD
    Why? By investigating individuals with SCA, we will gain valuable insights into the specific mechanisms through which the cerebellum participates in cognitive processes. Who? Healthy adults over the age of 18, who would like to participate as controls. What? Participation involves one clinic visit for 3-4 Hours, involving cognitive baseline measurements, an electroencephalography (EEG) and functional magnetic resonance imaging (fMRI) recording during which a decision-making two-step task will be performed. Cost to me? There is no cost involved for participating in the study. You will receive...
  • Principal Investigator:

    Philip L. De Jager, MD, PHD
    We're testing a new type of MRI scanner that's smaller and portable - like a mobile MRI unit. This makes it easier to provide brain scans to people who have difficulty traveling to hospitals or live far from medical centers. We'll be studying people with multiple sclerosis (MS) and similar brain conditions. Our goal is to learn how well this portable scanner can measure brain changes and how these changes relate to memory and thinking abilities. By validating this technology, we hope to make MRI scanning more accessible to everyone while advancing our understanding of conditions like MS. The...
  • Principal Investigator:

    Philip L. De Jager, MD, PHD
    The Snapshot study aims to understand brain and spinal cord aging in healthy individuals and individuals with multiple sclerosis (MS). We aim to identify new tools that will help us to achieve successful brain aging in the general population and in people with an underlying autoimmune disease. A critical aspect of this study is that we are looking for individuals who are willing to donate their brain and spinal cord when they pass away; this will enable the investigators to understand which molecules in the brain made someone more or less likely to age successfully. The brains will be housed...
  • Principal Investigator:

    Philip L. De Jager, MD, PHD
    MS Genetics aims to better understand the genetic component of demyelinating diseases by doing genetic testing on blood samples of participants. This study involves a one-time blood draw and completion of questionnaires spread out over a couple of years in hopes to better understand the genes that makes one predisposed to Multiple Sclerosis and various other demyelinating diseases.
  • Principal Investigator:

    Christiane Reitz, MD, PhD
    We are recruiting families with members under the age of 65 who have dementia or are experiencing memory problems. Our initial screening can be completed in person or over the phone. The evaluation will take about 1 to 1.5 hours per person and includes a: 1. Blood sample (5 tablespoons) or saliva (1 teaspoon) collection: These blood samples will allow us to examine genes to identify causative mutations. 2. Brief Neuropsychological Assessment. 3. Medical History: A research physician will collect basic medical information on you and your family. This assessment will provide information on...
  • Principal Investigator:

    Thomas H. Brannagan III, MD
    The main purpose of this study is to learn how the study drug (NMD670) works and how safe the study drug is compared with placebo. A placebo is an inactive material that looks like the study drug but does not have any active study drug. Researchers use a placebo to see if the study drug works better or is safer than taking nothing. You will be in this study for up to 8 weeks. During the study, you will visit the study center at least 6 times. If you are eligible to participate in this study, you will be seen by a doctor with expertise in CMT care who will be leading the research study at a...
  • Principal Investigator:

    Jennifer M. Bain, MD, PhD
    This is a Phase IIA Multicenter, open-label, 12-week study to investigate the pharmacokinetics and safety and to provide proof of mechanism of the drug, Alogabat (RO7017773) in children and adolescents aged 5-17 years old with Angelman Syndrome with the deletion genotype.
  • Principal Investigator:

    Sheng-Han Kuo, MD
    You may be eligible to take part in the study because you have a diagnosis of Multiple System Atrophy (MSA) with the symptoms of neurogenic Orthostatic Hypotension (nOH). MSA is a rare disorder in adults that progresses rapidly and ultimately is a fatal neurodegenerative disease. It is characterized by autonomic failure affecting blood pressure regulation, movement and balance. Autonomic failure occurs when the autonomic nervous system, which controls functions responsible for well-being and maintaining balance, does not regulate properly. The main purpose of this study is to look at...
  • Principal Investigator:

    Maria Diaz Ordonez, MD
    The main purpose of this study is to determine a dose of AZD9574 that is safe and tolerable (does not cause side effects that could prevent people from taking the drug) when given alone or in combination with temozolomide. The study will also evaluate how much of the study drug is in your blood at various times. In addition, the action of the study drug will be evaluated by measuring specific chemicals in the blood. All parts of this study are experimental which means AZD9574 is not approved by the U.S. Food and Drug Administration (FDA). This is the first time AZD9574 has been tested in...

Pages